Choriocarcinoma in a 73-year-old woman: a case report and review of the literature
Open Access
- 25 November 2010
- journal article
- review article
- Published by Springer Science and Business Media LLC in Journal of Medical Case Reports
- Vol. 4 (1), 379
- https://doi.org/10.1186/1752-1947-4-379
Abstract
Choriocarcinoma is a highly malignant tumor of trophoblastic origin. Most cases present within one year of the antecedent pregnancy (molar or non-molar). However, very rarely, choriocarcinoma can develop from germ cells or from dedifferentiation of endometrial carcinoma into choriocarcinoma. This article concerns a case of choriocarcinoma developing 38 years after the patient's last pregnancy and 23 years after menopause. A 73-year-old African-American woman presented with a three-week history of vaginal bleeding. A vaginal mass was seen on pelvic examination. Ultrasonography showed a thickened complex endometrial echo. Her β-human chorionic gonadotrophin level was found to be elevated (2,704,040 mIU/mL). Vaginal and uterine biopsies were suggestive of choriocarcinoma. Immunohistochemistry tests were positive for β-human chorionic gonadotrophin as well as cytokeratin and negative for octamer binding transcription factor 3/4 and α-fetoprotein, supporting the diagnosis of choriocarcinoma. A combination of etoposide, methotrexate, and dactinomycin, followed by cyclophosphamide and vincristine (the so-called EMA/CO regimen) was initiated. After seven cycles of chemotherapy, her β-human chorionic gonadotrophin level dropped below 5 mIU/mL. Our patient is being followed up at our oncology institute. We report an extremely rare case of choriocarcinoma arising 23 years after menopause. A postmenopausal woman presenting with vaginal bleed from a mass and β-human chorionic gonadotrophin elevation should be evaluated by immunohistochemical analysis to rule out the possibilities of a germ cell origin of the tumor or dedifferentiation of an epithelial tumor. Absence of octamer binding transcription factor 3/4, α-fetoprotein and CD-30 staining helps in exclusion of most germ cell tumors. DNA polymorphism studies can be used to differentiate between gestational and non-gestational tumor origin. These require fresh tissue samples and are time consuming. Finally, the effective first-line therapy for β-human chorionic gonadotrophin-producing high-risk gestational as well as non-gestational trophoblastic tumors is combination chemotherapy (the EMA/CO regimen). Therefore, treatment should be commenced when a potential diagnosis of metastatic trophoblastic tumor is being considered.Keywords
This publication has 25 references indexed in Scilit:
- New discoveries on the biology and detection of human chorionic gonadotropinReproductive Biology and Endocrinology, 2009
- Uterine Gestational Choriocarcinoma Developing After a Long Latent Period in a Postmenopausal Woman: The Value of DNA Polymorphism StudiesInternational Journal of Surgical Pathology, 2008
- Ovarian nongestational choriocarcinoma mixed with various epithelial malignancies in association with endometriosisGynecologic Oncology, 2006
- Primary non-gestational choriocarcinoma of the uterine cervix: A case reportGynecologic Oncology, 2005
- Germ cell tumors of the gonads: a selective review emphasizing problems in differential diagnosis, newly appreciated, and controversial issuesLaboratory Investigation, 2005
- Establishing a germ cell origin for metastatic tumors using OCT4 immunohistochemistryCancer, 2004
- Extraovarian nongestational choriocarcinoma in a postmenopausal womanInternational Journal of Gynecologic Cancer, 2004
- Carcinosarcoma of the Uterus Associated With a Nongestational ChoriocarcinomaSouthern Medical Journal, 2000
- Gestational trophoblastic disease in women aged 50 or moreGynecologic Oncology, 1985
- LATENT VAGINAL CHORIOCARCINOMA IN A POSTMENOPAUSAL WOMANActa Pathologica Japonica, 1976